{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T17:11:48Z","timestamp":1754154708371,"version":"3.41.2"},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T00:00:00Z","timestamp":1745884800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,7,24]]},"abstract":"<jats:p>Cannabinoid agonists, particularly those binding to cannabinoid receptor 2 (CB2), offer promising results for patients with inflammatory skin diseases such as dermatomyositis, as they can modulate inflammatory cytokines without the unwanted psychoactive adverse effects associated with cannabinoid compounds. Phase II clinical trials of selective CB2 agonists have shown good safety and efficacy data compared with placebo, although further data remain to be seen in current phase III trials. We highlight the benefits of complex treatment-resistant dermatomyositis in a patient who benefited greatly from an equivalent cannabinoid agonist.<\/jats:p>","DOI":"10.1093\/ced\/llaf176","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T21:50:36Z","timestamp":1745963436000},"page":"1687-1689","source":"Crossref","is-referenced-by-count":0,"title":["Cannabinoids in the management of refractory juvenile dermatomyositis: a patient\u2019s perspective"],"prefix":"10.1093","volume":"50","author":[{"given":"Rameen","family":"Wahaj","sequence":"first","affiliation":[{"name":"University of Dundee School of Medicine , Dundee ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sibel","family":"Demirel","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Ninewells Hospital and Medical School , Dundee ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Dawe","sequence":"additional","affiliation":[{"name":"Photobiology Unit, NHS Tayside , Dundee ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,4,29]]},"reference":[{"key":"2025072412171769200_llaf176-B1","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3346\/jkms.2009.24.4.715","article-title":"Clinical characteristics and outcomes of juvenile and adult dermatomyositis","volume":"24","author":"Na","year":"2009","journal-title":"J Korean Med Science"},{"key":"2025072412171769200_llaf176-B2","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1067\/mjd.2001.113686","article-title":"Juvenile dermatomyositis: a retrospective review of a 30-year experience","volume":"45","author":"Peloro","year":"2001","journal-title":"J Am Acad Dermatol"},{"key":"2025072412171769200_llaf176-B3","doi-asserted-by":"crossref","first-page":"652","DOI":"10.3390\/molecules25030652","article-title":"Cannabinoids in the pathophysiology of skin inflammation","volume":"25","author":"Scheau","year":"2020","journal-title":"Molecules"},{"key":"2025072412171769200_llaf176-B4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13075-021-02665-x","article-title":"Cannabinoid type 2 receptor (CB2R) distribution in dermatomyositis skin and peripheral blood mononuclear cells (PBMCS) and in vivo effects of lenabasum","volume":"24","author":"Maddukuri","year":"2022","journal-title":"Arthritis Res Ther"},{"key":"2025072412171769200_llaf176-B5","doi-asserted-by":"crossref","first-page":"2651","DOI":"10.1016\/j.jid.2022.03.029","article-title":"Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial","volume":"142","author":"Werth","year":"2022","journal-title":"Journal of Invest Dermatol"},{"key":"2025072412171769200_llaf176-B6","doi-asserted-by":"crossref","first-page":"100311","DOI":"10.1016\/j.xjidi.2024.100311","article-title":"Long-term safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: follow-up data from a 3-year open-label extension study","volume":"5","author":"Stone","year":"2025","journal-title":"JID Innov"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf176\/63029444\/llaf176.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1687\/63029444\/llaf176.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/8\/1687\/63029444\/llaf176.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,24]],"date-time":"2025-07-24T16:17:23Z","timestamp":1753373843000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/8\/1687\/8122001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":6,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,4,29]]},"published-print":{"date-parts":[[2025,7,24]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf176","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,8]]},"published":{"date-parts":[[2025,4,29]]}}}